Feed aggregator

KBRA Releases Monthly CMBS Trend Watch

Lastest from Businesswire - Thu, 01/04/2024 - 14:48
NEW YORK--(BUSINESS WIRE)-- #KBRA--KBRA releases the December 2023 issue of CMBS Trend Watch. The market ended 2023 on a positive note with the Federal Reserve signaling lower rates in 2024, spreads exhibiting signs of stability, and a recent treasury rally. While issuance was still meaningfully lower by 44% on a year-over-year (YoY) basis, indications suggest issuance in the new year may start off strong. Based on our current visibility there could be up to 12 deals that launch in January including si

Balfour Beatty’s US Operations Hires Kellie Ajjan as Senior Vice President of Human Resources

Lastest from Businesswire - Thu, 01/04/2024 - 14:48
DALLAS--(BUSINESS WIRE)--Balfour Beatty’s US Operations Hires Kellie Ajjan as Senior Vice President of Human Resources.

Summit Park Leads Majority Recapitalization of Michelli Weighing & Measurement

Lastest from Businesswire - Thu, 01/04/2024 - 14:48
CHARLOTTE, N.C. & NEW ORLEANS--(BUSINESS WIRE)--Summit Park is pleased to announce it has led a majority recapitalization of Michelli Weighing & Measurement (“Michelli” or the “Company”). Michelli is a leading test and measurement business providing calibration, maintenance, inspection, and installation services and products for industrial weighing equipment, precision measurement devices, and calibration equipment. The Company provides 24-hour mission-critical services and products to its

Biotech Veteran Marc Yoskowitz Named Evozyne CEO

Lastest from Businesswire - Thu, 01/04/2024 - 14:48
CHICAGO--(BUSINESS WIRE)--Chicago-based Evozyne today announced Marc Yoskowitz as CEO of the generative AI-driven biotech. Yoskowitz, most recently chief strategy officer and executive vice president, life sciences, at Tempus AI, will further develop the company’s strategy, focusing its generative AI platform on drug discovery in areas of high unmet patient need. Yoskowitz has held executive leadership positions with Pfizer, Hospira and McKinsey & Company, bringing deep biopharmaceutical, c

Pages